FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1155 October 26, 1995 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: We congratulate Dr. Hunter (June 22 issue)¹ on her timely review. It must be emphasized, however, that neuromuscular blocking drugs should be used only by practitioners who are skilled in airway management and respiratory support, and only after sufficient sedation and analgesia have been provided to patients, since these drugs are intrinsically devoid of any sedative, analgesic, or amnestic properties.²

To Hunter's description of the ideal neuromuscular blocking drug we would add that it should not interact with other drugs. Drugs known to potentiate the action of neuromuscular blockers include inhaled anesthetic agents, antibiotics (especially aminoglycosides), antiarrhythmic . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Amadori, S., Suciu, S., Jehn, U., Stasi, R., Thomas, X., Marie, J.-P., Muus, P., Lefrere, F., Berneman, Z., Fillet, G., Denzlinger, C., Willemze, R., Leoni, P., Leone, G., Casini, M., Ricciuti, F., Vignetti, M., Beeldens, F., Mandelli, F., De Witte, T., for the EORTC/GIMEMA Leukemia Groups, (2005). Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106: 27-34 [Abstract] [Full Text]